Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | MMP1 | P03956 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.51 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.51 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | ANPEP | P15144 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7042302 | 1.00 | ALDH1A1 (0.60) | ALDH1A1KMT2AMMP1MAPTITGB3 | |
| SCHEMBL6403555 | 0.84 | HTT (0.58) | ALDH1A1MMP1MAPTATMANPEP | |
| SCHEMBL15251955 | 0.84 | HTT (0.58) | ALDH1A1MMP1MAPTATMANPEP | |
| SCHEMBL4268532 | 0.82 | SMN1; SMN2 (0.63) | MAPT | |
| SCHEMBL21759695 | 0.82 | SMN1; SMN2 (0.63) | MAPT | |
| SCHEMBL15623775 | 0.78 | ALDH1A1 (0.62) | ALDH1A1KMT2AMAPT | |
| SCHEMBL28356153 | 0.78 | ALDH1A1 (0.64) | ALDH1A1KMT2AANPEP | |
| SCHEMBL14729380 | 0.78 | ALDH1A1 (0.57) | ALDH1A1KMT2AITGB3ITGA2B | |
| SCHEMBL18145530 | 0.78 | ALDH1A1 (0.57) | ALDH1A1KMT2AITGB3ITGA2B | |
| SCHEMBL4027352 | 0.77 | PLA2G2A (0.61) | ALDH1A1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030225061-A1 | Protease inhibitors | MARQUIS ROBERT WELLS (US) | 2003-12-04 | — | — | US | claimed |
| US-20030044399-A1 | Method of treatment | SMITHKLINE BEECHAM CORPORATION | 2003-03-06 | — | — | US | claimed |
| US-20030225061-A1 | Protease inhibitors | MARQUIS ROBERT WELLS (US) | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225061-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | ALDH1A1 3651/4885KMT2A 2920/4885MMP1 16/4885 |
| US-20030044399-A1 | Method of treatment | DNPEP, PEPD, ANPEP | ALDH1A1 1483/4885KMT2A 1833/4885MMP1 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.